Given the prevalence of MYCN-amplified tumors in the high-risk class, their relatively homogeneous genomic alteration profile (markedly different from that of non-MYCN-amplified tumors), their sheer aggressiveness2 and their unfavorable prognosis, we focused our analysis on this specific neuroblastoma subtype. The gene discussed is MYCN; the disease is neuroblastoma.